AMI Asset Management Corp Sells 16,475 Shares of Halozyme Therapeutics, Inc. $HALO

Key Points

• AMI Asset Management Corp decreased its stake in Halozyme Therapeutics by 45.6%, selling 16,475 shares and now holding 19,676 shares worth approximately $1,024,000.
• Halozyme Therapeutics reported a quarterly EPS of $1.54, exceeding estimates and achieving a revenue increase of 40.8% year-over-year, amounting to about $325.72 million.
• Analyst ratings for Halozyme are mixed, with one strong buy, five buys, four holds, and two sells, and a current consensus rating of "Hold" with an average target price of $69.89.

AMI Asset Management Corp trimmed its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 45.6% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 19,676 shares of the biopharmaceutical company's stock after selling 16,475 shares during the period. AMI Asset Management Corp's holdings in Halozyme Therapeutics were worth $1,024,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in HALO. Two Sigma Advisers LP bought a new stake in Halozyme Therapeutics in the 4th quarter worth about $282,000. Parallel Advisors LLC grew its position in shares of Halozyme Therapeutics by 12.5% during the 1st quarter. Parallel Advisors LLC now owns 1,875 shares of the biopharmaceutical company's stock valued at $120,000 after acquiring an additional 208 shares during the period. Rhumbline Advisers grew its position in shares of Halozyme Therapeutics by 1.7% during the 1st quarter. Rhumbline Advisers now owns 417,430 shares of the biopharmaceutical company's stock valued at $26,636,000 after acquiring an additional 6,922 shares during the period. Portside Wealth Group LLC grew its position in shares of Halozyme Therapeutics by 2.4% during the 1st quarter. Portside Wealth Group LLC now owns 9,317 shares of the biopharmaceutical company's stock valued at $595,000 after acquiring an additional 222 shares during the period. Finally, Sugar Maple Asset Management LLC grew its position in shares of Halozyme Therapeutics by 32.1% during the 1st quarter. Sugar Maple Asset Management LLC now owns 10,300 shares of the biopharmaceutical company's stock valued at $657,000 after acquiring an additional 2,500 shares during the period. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Stock Up 2.2%

HALO opened at $74.94 on Thursday. The company has a 50 day moving average of $69.97 and a 200 day moving average of $61.86. The company has a market cap of $8.77 billion, a PE ratio of 17.15, a price-to-earnings-growth ratio of 0.40 and a beta of 1.16. Halozyme Therapeutics, Inc. has a 12 month low of $42.01 and a 12 month high of $79.50. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, topping the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company had revenue of $325.72 million during the quarter, compared to the consensus estimate of $282.66 million. During the same period last year, the firm earned $0.91 EPS. Halozyme Therapeutics's revenue for the quarter was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analyst Ratings Changes

HALO has been the subject of a number of research reports. Wall Street Zen downgraded shares of Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 5th. JMP Securities increased their target price on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the company a "market outperform" rating in a research report on Wednesday, August 6th. The Goldman Sachs Group initiated coverage on shares of Halozyme Therapeutics in a research report on Thursday, July 10th. They set a "neutral" rating and a $55.00 target price for the company. Zacks Research raised shares of Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, September 2nd. Finally, Benchmark increased their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a "buy" rating in a research report on Wednesday, September 24th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $69.89.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 2,227 shares of the stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $77.95, for a total value of $173,594.65. Following the sale, the chief financial officer directly owned 22,079 shares in the company, valued at $1,721,058.05. This represents a 9.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bernadette Connaughton sold 2,000 shares of the stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $75.24, for a total transaction of $150,480.00. Following the completion of the sale, the director owned 44,952 shares in the company, valued at $3,382,188.48. This represents a 4.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 88,227 shares of company stock worth $6,020,595 in the last three months. 2.40% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.